Introduction
============

Endoscopic submucosal dissection (ESD) can use an en bloc resection procedure for superficial esophageal neoplasia, regardless of tumor size [@JR570-1] [@JR570-2]. However, stricture formation after ESD has been reported in 90 % of patients with a mucosal defect greater than 75 % of the circumference [@JR570-3], and stricture formation often leads to poor quality of life. In addition, frequent endoscopic balloon dilation (EBD) procedures are required to treat stricture formation, and repeated EBD increases medical costs and the risk of adverse events [@JR570-3].

Locoregional steroid injection and oral steroid administration are useful for preventing post-ESD stricture formation [@JR570-4] [@JR570-5] [@JR570-6] [@JR570-7] [@JR570-8] [@JR570-9]. However, oral steroids must be administered for at least 3 weeks, and it is difficult to treat some patients such as those with diabetes mellitus [@JR570-7] [@JR570-8] [@JR570-9] [@JR570-10] [@JR570-11]. Recent case reports indicated that polyglycolic acid (PGA) sheets, a biodegradable suture material, affixed with fibrin glue safely prevented esophageal stricture formation [@JR570-12] [@JR570-13]. However, the prevention rate was not sufficiently high, and the occurrence of stricture was higher than that after steroid therapy. In addition, a single prophylactic treatment with steroid injection or PGA sheets is ineffective for an entire-circumferential resection. Several cases of stricture formation after prophylactic steroid therapies have been reported [@JR570-4] [@JR570-5] [@JR570-6] [@JR570-11]. This higher rate of stricture formation might be due to baseline expansion of the circumference of the mucosal defect into an entire-circumference defect.

We investigated the prophylactic efficacy of hybrid therapy using a steroid injection and PGA sheets with fibrin glue to prevent stricture formation after esophageal ESD in high risk patients in whom we predicted stricture formation would be difficult to prevent with a single prophylactic steroid injection.

Materials and methods
=====================

Patients
--------

This retrospective case series was performed at Osaka City University. Between November 2013 and June 2015, 184 patients with 297 lesions from superficial esophageal neoplasias were treated with ESD in our hospital ([Fig. 1](#FI570-1){ref-type="fig"}). All patients provided written informed consent. The high risk population included the following: (1) patients who had single or multiple adjacent lesions and superficial esophageal neoplasms over 5/6 (83.3 %) of the esophageal circumference, which were predicted to be resected with a mucosal defect greater than or equal to 11/12 (91.7 %) of the esophageal circumference after ESD; patients who had single or multiple adjacent lesions and superficial esophageal neoplasms over 1/2 (50.0 %) of the esophageal circumference, which were predicted to be resected with a mucosal defect greater than 3/4 (75.0 %) of the esophageal circumference after ESD; (2) patients who had previously received radiotherapy for esophageal cancer; and (3) patients with lesions located near a previous scar from ESD or a surgical anastomosis site. Ten patients with a mucosal defect greater than or equal to 5/6 of the esophageal circumference who received hybrid therapy with a steroid injection and PGA sheets with fibrin glue were analyzed.

![ Study flow chart. \* One patient had both previous radiotherapy and lesion upon previous ESD scar. RT, previous radiotherapy.](10-1055-s-0042-111906-i570ei1){#FI570-1}

The main outcome measure was the incidence of stricture formation. Secondary outcomes were the number of EBDs needed to treat stricture formation and the occurrence of adverse events. The ethics committee of the Osaka City University Graduate School of Medicine approved this study (approval no.: 3340).

ESD procedure
-------------

A single-channel upper gastrointestinal endoscope (GIF-Q260J; Olympus, Tokyo, Japan) and a standard electrosurgical generator (VIO300D; ERBE Elektromedizin GmbH, Tübingen, Germany) were used. After delineating the tumor margins using iodine staining ([Fig. 2 a](#FI570-2){ref-type="fig"}), marking dots were placed using a bipolar needle-knife (B knife; XEMEX Co., Tokyo, Japan) or a monopolar needle-knife (Flush knife, DK2618JN; Fujifilm Medical, Tokyo, Japan). A hyaluronic acid solution was injected into the submucosal layer. After circumferential mucosal incision, submucosal dissection was performed ([Fig. 2 b](#FI570-2){ref-type="fig"}) [@JR570-2] [@JR570-5]. The lesion's size and mucosal defect were measured as a proportion of the esophageal circumference that was removed, based on its division into 12 equal parts ([Table 1](#TB570-1){ref-type="table"}) [@JR570-12].

![ Endoscopic appearance of hybrid therapy using locoregional steroid injection and polyglycolic acid (PGA) sheets with fibrin glue. Subtotal circumferential esophageal neoplasia was observed by chromoendoscopy with iodine staining (**a**), and circumferential endoscopic submucosal dissection (ESD) was performed (**b**). A steroid solution was carefully injected into the residual superficial submucosal layer (**c**). Pieces of PGA sheets were used to fill the mucosal defect using biopsy forceps. Subsequently, fibrin glue was applied to the PGA sheets (**d**). The PGA sheets remained in place upon observation on day 1 post-ESD (**e**). Endoscopic view showing that the ESD-induced ulceration improved without stricture and that a conventional upper gastrointestinal endoscope could be passed through the treatment site (**f**).](10-1055-s-0042-111906-i570ei2){#FI570-2}

###### Patients' characteristics.

  Patient                                Age, years; sex   Location                             Size of lesion   Size of mucosal defect   Longitudinal diameter, mm   Previous RT   Histological invasion depth   Additional treatment   Esophageal stricture   Sessions of EBD required   Follow-up period, days   Time to stricture, days
  -------------------------------------- ----------------- ------------------------------------ ---------------- ------------------------ --------------------------- ------------- ----------------------------- ---------------------- ---------------------- -------------------------- ------------------------ -------------------------
   1                                     75; male          Lower                                11               12                        90                         No            LPM                           None                   Yes                    1                          885                      49
   2                                     54; male          Lower                                12               12                        46                         No            MM                            Surgery                No                     0                           81                      
   3                                     72; male          Middle to Lower                      12               12                       100                         No            SM2                           Surgery                Yes                    1                           68                      32
   4                                     75; male          Upper to Middle                      12               12                       102                         No            SM2                           CRT                    Yes                    4, ongoing                 320                      65
   5                                     70; male          Middle                               11               12                        90                         No            LPM                           None                   No                     0                          542                      
   6                                     73; male          Upper to Middle                      11               11.5                     109                         No            MM                            CT                     No                     0                          410                      
   7[1](#FN570-1){ref-type="table-fn"}   65; female        Upper                                4 + 6            11                        51                         Yes           MM                            None                   No                     0                          320                      
   8[1](#FN570-1){ref-type="table-fn"}   74; male          Middle                               7                10                        42                         Yes           LPM                           None                   No                     0                          917                      
   9[2](#FN570-2){ref-type="table-fn"}   70; male          Upper on ESD scar                    11               12                        55                         Yes           SM2                           None                   Yes                    16, ongoing                444                      56
  10[2](#FN570-2){ref-type="table-fn"}   61; male          Upper anastomosis of esophagectomy   3 + 2 + 2        10                        25                         No            LPM                           None                   Yes                    7                          410                      49

The sizes of the lesion and mucosal defect were measured as the proportion of the esophageal circumference when divided into 12 equal parts. LPM, lamina propria; MM, muscularis mucosa; SM2, submucosal invasion ≥ 200 μm; RT, radiotherapy; CRT, chemoradiotherapy; CT, chemotherapy; EBD, endoscopic balloon dilation; ESD, endoscopic submucosal dissection.

Previously received radiotherapy for esophageal cancer.

Lesions located near a previous scar from endoscopic submucosal dissection (ESD) or a surgical anastomosis site.

Locoregional steroid injection and PGA sheet development
--------------------------------------------------------

A single session of triamcinolone acetonide (Kenacort; Bristol-Myers Squibb, Tokyo, Japan) was injected into the residual submucosal layer of the resected region immediately after ESD ([Video 1](#ME570-1){ref-type="media"}); 80 mg of triamcinolone acetonide was injected regardless of the size of the resected specimens, followed by 40 sequential injections of 0.5 mL (2 mg) of triamcinolone acetonide ([Fig. 2 c](#FI570-2){ref-type="fig"}) [@JR570-5]. Subsequently, pieces of PGA sheet (Neoveil; Gunze, Kyoto, Japan) were inserted to fill the mucosal defect using biopsy forceps without through-the-scope channel ([Fig. 2 d](#FI570-2){ref-type="fig"}) [@JR570-12]. Finally, we applied fibrinogen and thrombin solutions of fibrin glue (Beriplast P Combi-Set; CSL Behring Pharma, Tokyo, Japan) to the PGA sheets ([Fig. 2 e](#FI570-2){ref-type="fig"}). In the final four patients, we used the clip-and-pull method [@JR570-13]. Endoscopy was performed 2 days after ESD to confirm attachment of the PGA sheets and assess for adverse events [@JR570-12] [@JR570-13]. Then an oral diet was resumed.

**Video 1** After circumferential endoscopic submucosal dissection (ESD), a steroid solution was carefully injected into the residual superficial submucosal layer. Then, pieces of polyglycolic acid (PGA) sheets were used to fill the mucosal defect using biopsy forceps. Subsequently, fibrin glue was applied to the PGA sheets.

Follow-up and stricture formation
---------------------------------

Endoscopic evaluation of stricture formation was performed every 4 weeks after the procedure. When an ESD ulceration had not healed into a scar at 8 weeks, endoscopic examination was also performed 4 weeks later ([Fig. 2 f](#FI570-2){ref-type="fig"}). Esophageal stricture was considered present when a standard endoscope for the upper gastrointestinal tract, 9.2 mm in diameter, could not pass through the treatment site. When the patient presented with a chief complaint of dysphagia to semi-solid foods (dysphagia score 2) before examination, endoscopic evaluation was performed at that time. EBD was repeatedly performed when a stricture persisted either endoscopically or symptomatically.

Results
=======

Clinicopathological characteristics
-----------------------------------

Hybrid therapy was performed in (1) six patients who had superficial esophageal neoplasms greater than or equal to 11/12 of the circumferential defect, (2) two patients who had superficial esophageal neoplasms greater than or equal to 5/6 of the circumferential defect with a history of radiotherapy, (3) one patient who had a superficial esophageal neoplasm 5/6 of the circumferential defect located at a surgical anastomosis site, and (2) + (3) one patient who had an entire circumferential defect located on a previous scar from ESD and a history of radiotherapy ([Fig. 1](#FI570-1){ref-type="fig"}).

The clinicopathological characteristics of the 10 patients (nine men and one woman; median age 71.0 years) are shown in [Table 1](#TB570-1){ref-type="table"}. Two patients underwent en bloc resection of two adjacent lesions. Six patients had an entire circumferential defect and four had a sub-circumferential defect greater than or equal to 5/6 of the esophageal circumference. All neoplasias were resected en bloc with negative margins. Patient 2 underwent additional esophagectomy without stricture formation over 81 days. Patient 3 had stricture formation before another operation was performed, and it did not resolve within 68 days. Patient 6 underwent additional chemotherapy 85 days later, and patient 4 received additional chemoradiotherapy 160 days later.

Stricture formation
-------------------

Esophageal stricture formation occurred in five of 10 patients (50.0 %) ([Table 1](#TB570-1){ref-type="table"}). Stricture formation occurred in four of six (66.7 %) patients with entire circumferential defects and one of four (25.0 %) patients with sub-circumferential mucosal defects. The median duration between ESD and stricture confirmation of the first EBD was 49 days (range 32 -- 65).

The number of EBD sessions required to treat stricture formation was a median of 0.5 sessions (range 0 -- 16); two patients with refractory stricture still require EBD. No adverse events occurred associated with the prophylactic therapy, but one perforation associated with EBD was observed in patient 4 after chemoradiotherapy.

Subanalysis
-----------

We performed a subanalysis of eight patients excluding the patients with lesions located near a previous scar from ESD or surgical anastomosis site. Patient 9 had esophageal intramural pseudodiverticulosis, which is a rare cause of esophageal stricture, and he underwent ESD for esophageal cancer with 2/3 of a circumferential mucosal defect, chemoradiotherapy for local recurrence with an entire circumference, and entire circumferential salvage ESD for second recurrence with a sub-circumferential defect. Additionally, he had a moderate esophageal stricture. Patient 10 had a history of esophagectomy for esophageal cancer, and then he underwent total gastrectomy for gastric tube cancer, reconstruction of esophago-jejunal anastomosis, and ESD for three recurrent esophageal tumors that developed at the anastomosis site with mild stricture.

Esophageal stricture formation occurred in three of eight patients (37.5 %) with a median of 0 EBD sessions (range 0 -- 4) ([Table 1](#TB570-1){ref-type="table"}). All patients with stricture formation had undergone entire-circumferential resection (60.0 %, 3/5 patients), whereas no stricture formation occurred in the three patients with sub-circumferential mucosal defects.

Among six patients (five with entire circumferential defects, one with sub-circumferential defect) without a history of radiotherapy, stricture formation occurred in three (50.0 %) (median EBD sessions 0.5, range 0 -- 3).

Discussion
==========

Hybrid therapy using a locoregional steroid injection and PGA sheets with fibrin glue may have the potential to reduce stricture formation caused by ESD for superficial esophageal neoplasms in high risk patients in whom we predicted stricture formation would be difficult to prevent with a single steroid injection. Additionally, this combination therapy requires a low number of EBD sessions, even in patients with stricture formation.

Locoregional steroid injection reduces the incidence of stricture formation by approximately 10 -- 19 % with minimum adverse events in patients with more than 3/4 circumferential mucosal defect [@JR570-4] [@JR570-5]. However, an entire circumferential mucosal defect after ESD was difficult to prevent with several prophylactic therapies [@JR570-6] [@JR570-7] [@JR570-9] [@JR570-10] [@JR570-11] [@JR570-14]. Additionally, a tumor greater than 3/4 of the circumference was reported to be a risk factor for refractory stricture despite steroid injection [@JR570-14]. Furthermore, a history of radiotherapy and tumor recurrence on a previous scar from ESD and esophagectomy site were considered risk factors for stricture, and these cases with over 3/4 of a circumferential defect were considered to be a higher risk for stricture despite steroid injection. Therefore, we enrolled these high risk patients, because they require effective prophylactic therapy.

Overall, half of the patients had strictures, whereas 37.5 % of patients had strictures in the subanalysis. Thus, the therapy may not be effective for tumor recurrence on a previous scar from ESD and esophagectomy site with over a 5/6 circumferential mucosal defect. However, strictures were prevented in two patients with a history of radiotherapy. Because a history of radiotherapy was not reported as a risk factor for refractory stricture [@JR570-14], it may be acceptable to include these cases in the analysis. Stricture did not occur in eight patients with sub-circumferential defects even though we enrolled patients with larger circumferential defects compared to those in a previous report. As only 18.2 % of strictures occurred in another setting of hybrid therapy [@JR570-15], this treatment may have the potential to prevent stricture in patients with sub-circumferential defects. Fewer EBD sessions were needed to treat stricture formation in our study compared to previous studies (range 0 -- 1.7) ([Table 2](#TB570-2){ref-type="table"}) [@JR570-4] [@JR570-5] [@JR570-6] [@JR570-7] [@JR570-11] [@JR570-12] [@JR570-13].

###### Review of prophylactic therapy.

  First author and reference      Design                          Method                        Intervention                 N             Circumference of mucosal defect, %   Entire-circumference, n (%)            Follow-up period   Stricture rate, %                                 Sessions of EBD required
  ------------------------------- ------------------------------- ----------------------------- ---------------------------- ------------- ------------------------------------ -------------------------------------- ------------------ ------------------------------------------------- ------------------------------------------------
  Yamaguchi [@JR570-7]            Retrospective                   Oral steroid administration   Oral prednisolone            19            ≥ 75.0                                3 (15.8)                              NA                   5.3                                             1.7 (0 -- 7)[1](#FN570-3){ref-type="table-fn"}
  Isomoto [@JR570-10]             Retrospective                   Oral prednisolone              4                           100.0          4 (100)                             11 (5 -- 22) months                     50.0              3.3 (0 -- 11)[1](#FN570-3){ref-type="table-fn"}   
  Sato [@JR570-9]                 Retrospective                   Oral prednisolone             13                           100.0         13 (100)                             9 weeks                                100.0              13.8 ± 6.9[2](#FN570-4){ref-type="table-fn"}      
  Miwata [@JR570-11]              Retrospective                   Oral prednisolone             13                           100.0         13 (100)                             NA                                     100.0              \> 5, 67 %[3](#FN570-5){ref-type="table-fn"}      
  Hanaoka [@JR570-4]              Prospective historical          Steroid injection             Triamcinolone injection      30            ≥ 75.0                                0 (0)                                 2 months            10.0                                             0 (0 -- 2)[4](#FN570-6){ref-type="table-fn"}
  Nagami [@JR570-5]               Retrospective case controlled   Steroid injection             28                           73.7 ± 13.9    0 (0)                               2 months                                10.7              NA                                                
  Takahashi [@JR570-6]            RCT                             Triamcinolone injection       16                           ≥ 75.0         5 (31.3)                            16.1 ± 5.6 months                       62.5              6.1 ± 6.2[2](#FN570-4){ref-type="table-fn"}       
  Hanaoka [@JR570-14]             Retrospective                   Triamcinolone injection       12                           100.0         12 (100)                             NA                                      91.7              13 (0 -- 40)[4](#FN570-6){ref-type="table-fn"}    
  Miwata [@JR570-11]              Retrospective                   Prednisolone injection         6                           100.0          6 (100)                             NA                                     100.0              \> 5, 33 %[3](#FN570-5){ref-type="table-fn"}      
  Sakaguchi [@JR570-13]           Prospective one arm             PGA sheet with fibrin glue    PGA sheet with fibrin glue    8            ≥ 75.0                                NA                                    NA                  37.5                                             0.8 ± 1.2[2](#FN570-4){ref-type="table-fn"}
  Sakaguchi [@JR570-15]           Prospective one arm             Hybrid therapy                Hybrid therapy               11            ≥ 75.0                                2 (18.2)                              12 weeks            18.2                                             0 (0 -- 29)[4](#FN570-6){ref-type="table-fn"}
  Present study -- all patients   Retrospective one arm           Hybrid therapy                10                           ≥ 83.3         6 (60.0)                            2 months or until scarring confirmed    50                0.5 (0 -- 16)[4](#FN570-6){ref-type="table-fn"}   
  Present study -- subanalysis    Retrospective one arm           Hybrid therapy                 8                           ≥ 83.3         5 (71.4)                            2 months or until scarring confirmed    37.5              0 (0 -- 4)[4](#FN570-6){ref-type="table-fn"}      

EBD, endoscopic balloon dilatation; NA, not available; RCT, randomized controlled trial; PGA, polyglycolic acid.

Data expressed as mean (range).

Mean ± standard deviation.

Percentage of patients requiring EBD \> 5 times.

Median (range).

The higher incidence of stricture (60 %) was caused by a higher proportion of cases with entire circumferential defects. Several prophylactic therapies did not prevent stricture formation in most of these cases ([Table 2](#TB570-2){ref-type="table"}) [@JR570-9] [@JR570-10] [@JR570-11] [@JR570-14]. Since tissue contraction with centripetal movement of the landmarks in the esophageal mucosa is a normal part of the healing process of the ulcer [@JR570-16], residual mucosa and sub-circumferential resection play an important role in preventing stricture. In addition, 3.3 -- 13.8 or 10.4 EBD sessions were reported after oral or locoregional steroid therapy, respectively [@JR570-6] [@JR570-9] [@JR570-10] [@JR570-11], whereas a median of 1 (range 0 -- 4) was required in the present study. Miwata et al. showed that a longitudinal mucosal defect ≥ 5 cm was a risk factor for refractory stricture requiring more than five EBD sessions after an entire circumferential resection [@JR570-11]. However, fewer EBD sessions were required to treat stricture formation, even in those with mucosal defects ≥ 5 cm long ([Table 1](#TB570-1){ref-type="table"}). Our therapeutic methods may be useful for those with entire-circumferential mucosal defects.

Intralesional corticosteroid injection is thought to prevent stricture formation by inhibiting fibrosis and inflammation [@JR570-5]. Although the detailed mechanisms remain unknown, Iizuka et al. speculated that PGA sheets with fibrin glue shield the surface of the ESD ulceration and protect it from buccal secretions and food, thus inhibiting inflammation, because PGA sheets with fibrin glue prevent scar formation and contraction after glossectomy [@JR570-12]. Hybrid therapy using steroid injection and PGA sheets likely has additive or synergistic effects. We hope that the detailed mechanisms will be elucidated in basic studies.

Our study has several limitations. First, this was a retrospective case series with a small sample size. Large, prospective, randomized studies are needed. Second, the delivery of the PGA sheets was technically difficult and lengthy, thus the development of a new, easier delivery system is needed. Third, the inclusion of additional therapy may have affected our outcomes. However, the incidence of stricture formation may be accurate; scarring without stricture was confirmed in patient 9 before esophagectomy, and stricture was confirmed in the other patients before esophagectomy or chemoradiotherapy. Yet, this could have affected the number of EBD sessions.

Hybrid therapy using a locoregional steroid injection and PGA sheets with fibrin glue may have the potential to prevent esophageal stricture after ESD for superficial esophageal neoplasms in high risk patients.
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